(IBB) iShares Biotechnology - Ratings and Ratios
Exchange: NASDAQ • Country: USA • Currency: USD • Type: Etf • ISIN: US4642875565
IBB: Biotechnology, Stocks, Futures, Options, Cash
The iShares Biotechnology ETF ETF (NASDAQ:IBB) is an investment vehicle that tracks the performance of the biotechnology sector. The
With a strong presence in the US market, the fund is designed to provide exposure to a diversified portfolio of biotechnology stocks, primarily investing at least 80% of its assets in the underlying indexs component securities.
The funds investment strategy also allows for up to 20% of its assets to be allocated to futures, options, swaps, cash, and cash equivalents,, enhancing its flexibility in responding to market conditions.
As a non-diversified fund, IBB is particularly sensitive to the performance of its the biotechnology sector, which can be characterized by high volatility. For more information, you can visit the official iShares website at http://www.ish.com.
Analyzing the funds recent performance, we observe that it has been trending upwards, with its last price recorded at $106.96. While its 52-week high and low were $149.06 and $112.02, respectively, indicating a significant level of volatility.
Additional Sources for IBB ETF
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
IBB ETF Overview
| Market Cap in USD | 5,345m |
| Category | Health |
| TER | 0.45% |
| IPO / Inception | 2001-02-05 |
IBB ETF Ratings
| Growth Rating | -25.2 |
| Fundamental | - |
| Dividend Rating | 27.5 |
| Rel. Strength | -13.3 |
| Analysts | - |
| Fair Price Momentum | 112.64 USD |
| Fair Price DCF | - |
IBB Dividends
| Dividend Yield 12m | 0.29% |
| Yield on Cost 5y | 0.30% |
| Annual Growth 5y | 4.59% |
| Payout Consistency | 51.3% |
| Payout Ratio | % |
IBB Growth Ratios
| Growth Correlation 3m | -13.4% |
| Growth Correlation 12m | -77.3% |
| Growth Correlation 5y | -30.4% |
| CAGR 5y | -0.13% |
| CAGR/Max DD 5y | 0.00 |
| Sharpe Ratio 12m | -0.18 |
| Alpha | -16.68 |
| Beta | 0.818 |
| Volatility | 23.16% |
| Current Volume | 3169.2k |
| Average Volume 20d | 2023.4k |
As of June 17, 2025, the stock is trading at USD 128.00 with a total of 3,169,249 shares traded.
Over the past week, the price has changed by +0.32%, over one month by +7.35%, over three months by -5.87% and over the past year by -5.24%.
Probably not. Based on ValueRay´s Analyses, iShares Biotechnology (NASDAQ:IBB) is currently (June 2025) not a good stock to buy. It has a ValueRay Growth Rating of -25.23 and therefor a somwhat technical negative rating according to historical growth.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of IBB is around 112.64 USD . This means that IBB is currently overvalued and has a potential downside of -12%.
iShares Biotechnology has no consensus analysts rating.
According to our own proprietary Forecast Model, IBB iShares Biotechnology will be worth about 127.3 in June 2026. The stock is currently trading at 128.00. This means that the stock has a potential downside of -0.53%.
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 127.3 | -0.5% |